BEX2 Is Overexpressed in a Subset of Primary Breast Cancers and Mediates Nerve Growth Factor/Nuclear Factor-κB Inhibition of Apoptosis in Breast Cancer Cell Lines
Open Access
- 15 July 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (14), 6725-6736
- https://doi.org/10.1158/0008-5472.can-06-4394
Abstract
We have identified a novel subtype of estrogen receptor (ER)-positive breast cancers with improved outcome after tamoxifen treatment and characterized by overexpression of the gene BEX2. BEX2 and its homologue BEX1 have highly correlated expression and are part of a cluster enriched for ER response and apoptosis genes. BEX2 expression is induced after estradiol (E2) treatment with a peak at 3 h, suggesting BEX2 is an estrogen-regulated gene. BEX2 belongs to a family of genes, including BEX1, NGFRAP1 (alias BEX3), BEXL1 (alias BEX4), and NGFRAP1L1 (alias BEX5). Both BEX1 and NGFRAP1 interact with p75NTR and modulate nerve growth factor (NGF) signaling through nuclear factor-κB (NF-κB) to regulate cell cycle, apoptosis, and differentiation in neural tissues. In breast cancer cells, NGF inhibits C2-induced apoptosis through binding of p75NTR and NF-κB activation. Here, we show that BEX2 expression is necessary and sufficient for the NGF-mediated inhibition (through NF-κB activation) of C2-induced apoptosis. We also show that BEX2 modulates apoptosis of breast cancer cells in response to E2 (50 nmol/L) and tamoxifen (5 and 10 μmol/L). Furthermore, BEX2 overexpression enhances the antiproliferative effect of tamoxifen at pharmacologic dose (1 μmol/L). These data suggest that a NGF/BEX2/NF-κB pathway is involved in regulating apoptosis in breast ancer cells and in modulating response to tamoxifen in primary tumors. [Cancer es 2007;67(14):6725–36]Keywords
Other Versions
This publication has 54 references indexed in Scilit:
- Genome-wide analysis of estrogen receptor binding sitesNature Genetics, 2006
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate CancerScience, 2005
- NF-κB inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifenAnnals Of Oncology, 2004
- Expression of a novel lacrimal gland gene lacritin in human breast tissuesZeitschrift für Krebsforschung und Klinische Onkologie, 2003
- Breast cancer classification and prognosis based on gene expression profiles from a population-based studyProceedings of the National Academy of Sciences of the United States of America, 2003
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences of the United States of America, 2003
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001
- 17β-Estradiol Inhibits Tumor Necrosis Factor-α-Induced Nuclear Factor-κB Activation by Increasing Nuclear Factor-κB p105 Level in MCF-7 Breast Cancer CellsBiochemical and Biophysical Research Communications, 2000